<DOC>
	<DOCNO>NCT01373008</DOCNO>
	<brief_summary>Premature infant chronic lung disease ( bronchopulmonary dysplasia [ BPD ] ) commonly treat inhaled steroid , optional treatment accord textbook guideline . However , evidence support treatment spontaneously breathe infant limit , base two randomized , placebo-controlled trial ( RCT ) relative small number infant . The Cochrane review conclude study allow firm conclusion regard efficacy inhaled steroid non-ventilated infant . Thus , doubt need RCT order ascertain role inhale steroid infant BPD . Because physical property theoretically make QVAR attractive therapy infant study show effective similar safety profile inhale steroid child , investigator hypothesize inhaled QVAR effective therapy infant BPD .</brief_summary>
	<brief_title>Inhaled Extra-fine Hydrofluoalkane-beclomethasone ( QVAR ) Premature Infants With Bronchopulmonary Dysplasia ( BPD )</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Bronchopulmonary Dysplasia</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>1 . Preterm infant moderate severe BPD , define oxygen &lt; 30 % , &gt; 30 % positive pressure support 36 week correct gestational age , respectively 2 . Parents sign informed consent 3 . The parent comply 3 month study followup requirement , judge site principal investigator . 1 . Congenital malformation 2 . Cardiac disease ( include active PDA ) 3 . Intraventricular hemorrhage grade IIIIV 4 . Unstable condition sepsis , apneas , ets . time enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Inhaled steroid</keyword>
	<keyword>bronchopulmonary dysplasia</keyword>
	<keyword>Infants moderate severe BPD</keyword>
</DOC>